Pulmonary vascular disease & thromboembolism
Refined Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: Initial Results of U.S. Regional Program
Authors' conclusion
This single center study from the US showed that BPA with refined techniques in patients with CTEPH was safe and was associated with significant improvements in pulmonary hemodynamics and functional capacity.
Study context
- Population
- Patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing balloon pulmonary angioplasty (BPA) at Temple University Hospital, US211 BPA sessions
- Participants
- 77 patients
- Exposure
- Post-BPA vs baseline
- BPAn = 77
- Outcome
- Change in PVR after BPA vs baseline; primary safety endpoint: hemoptysis
- Follow-up
- Hemoptysis within 24 hours
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
PVR change vs baseline
- Mean pulmonary vascular resistance (PVR) improved by
- 26%
- P
- P<0.001
Observational data: associations, not effects.
Secondary outcomes
6MWD
- Mean 6MWD improved by 71.7 meters
- P < 0.001
WHO functional class
- Improved by one functional class
- P < 0.001
Factors associated with improved functional and hemodynamic response
- Pre-procedural riociguat, reduced baseline PA compliance, >3 BPA sessions per patient (independent factors)
Safety
Hemoptysis (primary safety endpoint) · within 24 hours
- BPA sessions complicated by hemoptysis
- 10 (4.7%)
- Per session; 211 sessions
Original publication
Refined Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: Initial Results of U.S. Regional Program. JACC Adv. Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →